Novartis issued a letter to US health professionals on October 19, 2006 regarding the small risk of congestive heart failure from imatinib (Gleevec). The letter is posted on the website of the FDA (link to letter). The Prescribing Information document has also been updated to include the new warning. See our earlier news story for details.